Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin
- PMID: 1884735
- DOI: 10.1007/BF00279969
Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin
Abstract
The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission. Doses of 5, 10, 20 and 40 mg omeprazole were given once daily for 7 consecutive days and the basal (BAO) and peak (PAO) acid output and fasting plasma gastrin concentration were measured 24 h after the seventh dose. Omeprazole suppressed PAO significantly and dose-dependently after doses of 10, 20 and 40 mg, the suppression being 42%, 75% and 85%, respectively. No patient showed complete inhibition of PAO and at least 20 mg had to be given to obtain a marked inhibitory effect in all patients. Increasing the dose to 40 mg had only a slight additional effect compared to 20 mg. There was a relationship between degree of acid inhibition and the increase in fasting plasma gastrin. PAO had to be suppressed by more than 80% before a moderate increase in fasting plasma gastrin was observed. The optimal once-daily oral dose of omeprazole for inhibition of acid secretion in elderly patients appears to be 20 mg. Omeprazole 20-40 mg may cause a moderate increase in fasting plasma gastrin.
Similar articles
-
Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients.Hepatogastroenterology. 1992 Aug;39(4):366-70. Hepatogastroenterology. 1992. PMID: 1427586 Clinical Trial.
-
Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients.Gut. 1988 Dec;29(12):1715-20. doi: 10.1136/gut.29.12.1715. Gut. 1988. PMID: 3220312 Free PMC article.
-
Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment.Scand J Gastroenterol. 1988 Dec;23(10):1259-66. doi: 10.3109/00365528809090202. Scand J Gastroenterol. 1988. PMID: 3249924
-
Effect of omeprazole on gastric acid secretion and plasma gastrin in man.Scand J Gastroenterol Suppl. 1989;166:27-32; discussion 41-2. doi: 10.3109/00365528909091240. Scand J Gastroenterol Suppl. 1989. PMID: 2690329 Review.
-
Effect of omeprazole on gastric acid secretion and plasma gastrin.J Gastroenterol Hepatol. 1989;4 Suppl 2:19-25. J Gastroenterol Hepatol. 1989. PMID: 2491358 Review.
Cited by
-
Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.Br J Clin Pharmacol. 1995 Jan;39(1):15-23. doi: 10.1111/j.1365-2125.1995.tb04404.x. Br J Clin Pharmacol. 1995. PMID: 7756094 Free PMC article. Clinical Trial.
-
Prescribing policy for antiulcer treatment in the elderly.Drugs Aging. 1993 Jul-Aug;3(4):308-19. doi: 10.2165/00002512-199303040-00002. Drugs Aging. 1993. PMID: 8369591 Review.
-
Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.Drugs Aging. 1996 Oct;9(4):251-61. doi: 10.2165/00002512-199609040-00003. Drugs Aging. 1996. PMID: 8894523 Review.
-
Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.Pharmacoeconomics. 1993 Jun;3(6):482-510. doi: 10.2165/00019053-199303060-00008. Pharmacoeconomics. 1993. PMID: 10146883 Review.
-
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002. Clin Pharmacokinet. 1996. PMID: 8827397 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources